专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

MA40344A COMBINAISON D'UN ANTAGONISTE DE PD-1 ET D'UN VACCIN À BASE DE LISTERIA POUR LE TRAITEMENT DU CANCER 未知
公开(公告)号：MA40344A
公开(公告)日：2016-01-21
申请号：MA40344
申请日：2015-07-17
申请人： ADVAXIS INC , MERCK SHARPE AND DOHME CORP
发明人： MAURO DAVID J , PERINI RODOLFO F , PETIT ROBERT
IPC分类号： A61K39/02 , A61K35/74 , A61K39/12 , A61P35/00
摘要： La présente invention concerne des polythérapies comprenant un antagoniste du récepteur de mort programmée 1 (pd -1) et une souche de listeria qui exprime un antigène spécifique des tissus de la prostate (psa), et l'utilisation de polythérapies pour le traitement du cancer de la prostate.

2. 发明专利

CA2955612A1 COMBINATION OF A PD-1 ANTAGONIST AND A LISTERIA-BASED VACCINE FOR TREATING PROSTATE CANCER 未知
公开(公告)号：CA2955612A1
公开(公告)日：2016-01-21
申请号：CA2955612
申请日：2015-07-17
申请人： ADVAXIS INC , MERCK SHARPE AND DOHME CORP
发明人： PETIT ROBERT , MAURO DAVID J , PERINI RODOLFO F
IPC分类号： A61K39/02 , A61K35/74 , A61K39/12 , A61P35/00
摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.

3. 发明专利

SG11201701149SA COMBINATION OF A PD-1 ANTAGONIST AND A LISTERIA-BASED VACCINE FOR TREATING PROSTATE CANCER 未知
公开(公告)号：SG11201701149SA
公开(公告)日：2017-04-27
申请号：SG11201701149S
申请日：2015-07-17
申请人： ADVAXIS INC , MERCK SHARPE AND DOHME CORP
发明人： PETIT ROBERT , MAURO DAVID J , PERINI RODOLFO F
IPC分类号： A61K39/02 , A61K35/74 , A61K39/12 , A61P35/00
摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.

4. 发明公开

KR20180043381A 재조합 리스테리아 백신 균주 및 암 면역요법에서 이를 이용하는 방법 审中-公开
公开(公告)号：KR20180043381A
公开(公告)日：2018-04-27
申请号：KR20187010508
申请日：2016-09-16
申请人： ADVAXIS INC
发明人： PETIT ROBERT , MAURO DAVID J
IPC分类号： A61K39/02 , A61K39/00 , A61K48/00
CPC分类号： A61K39/02 , A61K2039/585 , C07K14/005 , C07K14/195 , C07K2319/00 , C07K2319/70 , C12N2710/20022 , C12N2710/20034
摘要： 본발명은자궁경부암을치료하는방법으로서, 인간유두종바이러스항원을발현하는재조합를포함하는조성물을대상물에투여하는단계를포함하는방법을제공한다. 다른구현예에서, 본발명은자궁경부암을치료하는방법으로서, 화학방사선요법과인간유두종바이러스항원을발현하는재조합균주를포함하는병용요법을투여하는단계를포함하는방법을제공한다.

5. 发明公开

KR20180056782A 재조합 리스테리아 백신 균주 및 암 면역요법에서 이를 이용하는 방법 审中-公开
公开(公告)号：KR20180056782A
公开(公告)日：2018-05-29
申请号：KR20187013256
申请日：2016-10-14
申请人： ADVAXIS INC
发明人： PETIT ROBERT , PERRY KYLE
IPC分类号： C12N15/74 , A61K39/00 , A61K39/02 , A61K39/12 , A61K39/39 , C07K14/005 , C07K14/195
CPC分类号： C07K14/195 , A61K39/02 , A61K39/12 , C07K2319/55 , C12N2710/20034
摘要： 본발명은인간유두종바이러스관련종양또는암을치료하고, 이로부터보호하고, 이에대한면역반응을유도하는방법으로서, 적어도하나의인간유두종바이러스항원을포함하는작제물을발현하는재조합균주를대상물에투여하는단계를포함하는방법을제공한다.

6. 发明申请

WO2016126876A3 LISTERIA-BASED ADJUVANTS 审中-公开
标题翻译：李斯特菌为基础的佐剂
公开(公告)号：WO2016126876A3
公开(公告)日：2016-10-27
申请号：PCT/US2016016452
申请日：2016-02-03
申请人： ADVAXIS INC
发明人： PETIT ROBERT
IPC分类号： A61K39/39 , A61K35/74 , A61K39/02 , A61K48/00 , C07K14/195 , C12N9/10 , C12N9/16 , C12N9/88 , C12N15/74
CPC分类号： A61K35/74 , A61K39/001 , A61K39/0208 , A61K39/39 , A61K48/00 , A61K2039/522 , A61K2039/577 , A61K2039/585 , C07K14/195 , C07K14/335
摘要： This disclosure provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject. In certain instances, methods of this disclosure may be useful for subjects receiving a transplant.
摘要翻译：本公开提供了用于使用单核细胞增生利斯特氏菌作为佐剂以增强受试者的免疫应答的方法和组合物。在某些情况下，本公开的方法可用于接受移植物的受试者。

7. 发明申请

WO2015134722A3 METHODS AND COMPOSITIONS FOR INCREASING A T-EFFECTOR CELL TO REGULATORY T CELL RATIO 审中-公开
标题翻译：增加T效应细胞调节T细胞比率的方法和组合物
公开(公告)号：WO2015134722A3
公开(公告)日：2015-10-29
申请号：PCT/US2015018915
申请日：2015-03-05
申请人： ADVAXIS INC , NAT INST OF HEALTH NIH U S DEPT OF HEALTH AND HUMAN SERVICES DHHS U S GOVERNMENT NIH DIVISION OF EXT
发明人： PETIT ROBERT , WALLECHA ANU , CHEN ZHISONG , BERZOFSKY JAY A , KHLEIF SAMIR
IPC分类号： A61K39/02
CPC分类号： A61K39/0011 , A61K2039/523 , A61K2039/5254 , A61K2039/57 , A61K2039/572 , A61K2039/585 , A61K2039/6037 , C12N2710/20022 , C12N2710/20034 , C12N2710/20071
摘要： The present invention is directed to methods for increasing T-cell effector cell to regulatory T cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and tumor-associated antigen.
摘要翻译：本发明涉及用于将T细胞效应细胞增加至调节性T细胞比率的方法。本发明还涉及治疗，防止和诱导针对肿瘤的免疫应答的方法，包括向受试者施用重组李斯特氏菌菌株的步骤，所述重组李斯特菌菌株包含含有LLO片段和肿瘤相关抗原的融合肽。

8. 发明申请

WO2016191545A4 PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF 审中-公开
标题翻译：个性化交付矢量的免疫及其用途
公开(公告)号：WO2016191545A4
公开(公告)日：2017-02-09
申请号：PCT/US2016034301
申请日：2016-05-26
申请人： ADVAXIS INC
发明人： PETIT ROBERT , PERRY KYLE , PRINCIOTTA MICHAEL F , O'CONNOR DANIEL J
IPC分类号： A61K48/00 , A61K38/16 , C07K14/195 , C12N15/74
CPC分类号： C07K14/195 , A61K39/0011 , A61K48/00 , A61K2039/523 , C12N15/62 , C12N2710/20034
摘要： This invention provides a system of providing and creating personalized immunotherapeutic compositions for a subject having a disease or condition, including therapeutic immunotherapy delivery vectors and methods of making the same comprising gene expression constructs expressing peptides associated with one or more neo-epitopes or peptides containing mutations that are specific to a subject's cancer or unhealthy tissue. A delivery vector of this invention includes bacterial vectors including Listeria bacterial vectors; or viral vectors, peptide immunotherapy vectors; or DNA immunotherapy vectors, comprising one or more fusion proteins comprising one or more peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject. This invention also provides methods of using the same for inducing an immune response against a disease or condition, including a tumor or cancer, or an infection, or an autoimmune disease or an organ transplant rejection in the subject.
摘要翻译：本发明提供了一种为具有疾病或病症的受试者提供和创造个性化的免疫治疗组合物的系统，包括治疗性免疫治疗递送载体及其制备方法，其包含表达与一个或多个新表位或肽相关的肽的基因表达构建体，其含有突变这是特定于受试者的癌症或不健康的组织。本发明的递送载体包括细菌载体，包括李斯特菌属细菌载体; 或病毒载体，肽免疫治疗载体; 或DNA免疫治疗载体，其包含一种或多种包含一种或多种包含存在于从受试者获得的患有疾病的生物样品中的新表位的肽的融合蛋白。本发明还提供了使用其来诱导针对受试者中包括肿瘤或癌症，感染或自身免疫疾病或器官移植排斥的疾病或病症的免疫应答的方法。

9. 发明申请

WO2016154412A9 COMBINATION OF A PD-1 ANTAGONIST AND A LISTERIA BASED VACCINE FOR TREATING PANCREATIC CANCER 审中-公开
标题翻译： PD-1拮抗剂和基于LISTERIA的疫苗组合治疗胰腺癌
公开(公告)号：WO2016154412A9
公开(公告)日：2016-11-17
申请号：PCT/US2016023969
申请日：2016-03-24
申请人： UNIV PENNSYLVANIA , ADVAXIS INC
发明人： BEATTY GREGORY L , KNOBLOCK DAWSON , PETIT ROBERT , PRINCIOTTA MICHAEL F , WALLECHA ANU
IPC分类号： A61K39/12 , A61K39/395 , A61K48/00 , A61P35/00
CPC分类号： A61K39/12 , A61K39/00 , A61K39/395 , A61K48/00 , A61K2039/55544 , A61K2039/585

10. 发明公开

EP3107566A4 BIOMARKER DIRECTED MULTI-TARGET IMMUNOTHERAPY 无效
公开(公告)号：EP3107566A4
公开(公告)日：2017-10-11
申请号：EP15751948
申请日：2015-02-18
申请人： ADVAXIS INC
发明人： PETIT ROBERT
IPC分类号： A61K39/00 , A61K39/02 , A61K45/06 , C07K14/195 , C12Q1/68 , G01N33/574
CPC分类号： A61K39/0208 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/52 , A61K2039/522 , A61K2039/53 , A61K2039/572 , C07K14/195 , C07K2319/00 , C07K2319/95 , C12Q1/6886 , C12Q2600/158 , G01N33/574
摘要： This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted Listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a. obtaining a biological sample from said subject; b. evaluating the expression of a predetermined number of biomarkers in said biological sample; c. administering to said subject a composition comprising a recombinant Listeria strain, said strain comprising a nucleic acid sequence encoding at least one fusion protein, wherein said fusion protein comprises a biomarker identified in said biological sample, wherein said biomarker is associated with said disease, wherein said biomarker is fused to a PEST-containing polypeptide, and wherein each fusion protein within said Listeria comprises a different biomarker, thereby treating said disease in said subject.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式